GAO Report On Part D May Dampen Congressional Enthusiasm For POS Rebates
Executive Summary
Legislation redirecting manufacturer rebates on prescription drugs to the point of sale could face an uphill battle following report’s description of the way rebates lower costs in Medicare Part D.
You may also be interested in...
Rx Pricing, Rebating Should Be Back To Business As Usual In 2020, PBMs Say
Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.
Drug Pricing Bill: Senate Sponsors ‘Not Backing Down’ From Inflation Rebates
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.
The Role Of Rebates In Medicare Part D: So What Exactly Do They Do?
A US Government Accountability Office Report brings significant new data to the debate over the role of rebates in the Medicare prescription drug program – and makes a complex issue even more complicated.